Imatinib Arrow Lab

Imatinib, the active ingredient in Imatinib Arrow Lab, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients by targeting malignant cell signaling pathways.

GNH USA supplies Imatinib Arrow Lab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across EU and global markets through validated manufacturing and distribution processes.

Imatinib is a tyrosine kinase inhibitor used in oncology to target specific molecular abnormalities.

- Chronic Myeloid Leukemia: reduces leukemic cell proliferation and improves survival. - Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia: induces remission by inhibiting BCR‑ABL signaling. - Gastrointestinal Stromal Tumor: controls tumor growth by blocking c‑KIT and PDGFR activity.

Imatinib may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Fatigue: generalized tiredness. - Muscle cramps: intermittent painful contractions.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: congestive heart failure or reduced left ventricular function. - Severe neutropenia: marked decrease in neutrophil count increasing infection risk.

When prescribing Imatinib, clinicians should consider several safety and handling precautions.

- Baseline monitoring: obtain complete blood count, liver function tests, and renal function before initiating therapy. - Hepatic impairment: adjust therapy and monitor liver enzymes regularly in patients with liver disease. - Cardiac function: assess cardiac status in patients with pre‑existing heart conditions. - Drug interactions: review concomitant medications for potential CYP3A4 modulators. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with obstetric specialist. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Imatinib can interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce imatinib plasma concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase imatinib exposure and toxicity. - Antacids containing aluminum or magnesium: may decrease oral absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Acid‑suppressing agents (proton pump inhibitors, H2 blockers): may modestly reduce absorption; separate dosing by at least 2 hours. - Concomitant chemotherapy (e.g., cytarabine): may enhance myelosuppression. - Warfarin: monitor INR as imatinib may potentiate anticoagulant effect.